Eli Lilly and Company

Eli Lilly and Company is an American pharmaceutical company that discovers, develops, manufactures, and markets human medicines across four therapeutic areas — cardiometabolic health, oncology, immunology, and neuroscience — generating $65.2 billion in revenue in fiscal 2025. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, the company has grown into one of the world's most valuable pharmaceutical enterprises, with a market capitalization exceeding $1 trillion as of mid-2026.

Lilly is the story of a 150-year-old pharmaceutical incumbent that, after a decade in the shadow of patent expirations and a thinning pipeline, executed one of the most dramatic turnarounds in industry history. The catalyst was tirzepatide, a dual GIP/GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, which together accounted for 56% of 2025 revenue and nearly all of the company's growth. The question now is whether Lilly can sustain that momentum — managing a portfolio whose growth is so concentrated in one therapeutic mechanism, defending its incretin franchise against formidable competition, and building credible second and third growth engines from the rest of its pipeline — before the market prices the concentration as fragility rather than strength.

This file turns on a single question: is Lilly's current valuation — roughly 41 times trailing earnings and 15 times revenue — a rational price for a business with industry-leading growth, or does it embed assumptions about the durability of incretin economics that will prove optimistic? The answer depends on how you frame the company. If Lilly is an incretin pure-play riding an historic demand wave, the multiple must be judged against the life cycle of a single drug class. If it is a diversified innovation platform whose incretin success funded a pipeline that will produce the next wave, it is something else entirely.